Table 2 Overall proportion (low and high estimates) of cases targeted by a quadrivalent or a nonavalent HPV vaccine
From: Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France
Low estimate | High estimate | ||
|---|---|---|---|
Invasive cervical cancers (EDITH I) | Quadrivalent | 69.2 [64.4-73.9] | 82.2 [78.5-85.8] |
Nonavalent | 84.5 [81.0-87.8] | 92.1 [89.5-94.3] | |
Absolute additional Impact* (% of additional prevented cases) | 15.3% (p < 0.001) | 9.9% (p < 0.001) | |
Relative additional Impact** | 22.1% | 12.0% | |
High-grade cervical neoplasias (EDITH II) | Quadrivalent | 43.4 [36.9-50.0] | 64.7 [59.6-69.9] |
Nonavalent | 76.7 [72.2-81.0] | 89.5 [86.4-92.3] | |
Absolute additional Impact (% of additional prevented cases) | 33.3% (p < 0.001) | 24.7% (p < 0.001) | |
Relative additional Impact | 76.6% | 38.2% | |
Low-grade squamous intraepithelial lesions (EDITH III) | Quadrivalent | 13.6 [5.6-24.1] | 33.5 [25.6-41.4] |
Nonavalent | 25.9 [17.5-35.0] | 56.2 [49.8-62.8] | |
Absolute additional Impact (% of additional prevented cases) | 12.3% (p < 0.001) | 22.7% (p < 0.001) | |
Relative additional Impact | 90.7% | 67.7% | |
External acuminata condylomata (EDITH IV) | Quadrivalent | 63.1 [57.3-68.9] | 88.2 [84.7-91.4] |
Nonavalent | 68.6 [63.1-73.8] | 90.3 [87.2-93.2] | |
Absolute additional Impact (% of additional prevented cases) | 5.4% (p = 0.095) | 2.1% (p = 0.318) | |
Relative additional Impact | 8.6% | 2.4% | |
Anal cancers (EDITH V) | Quadrivalent | 70.5 [64.7-76.0] | 84.7 [80.6-88.7] |
Nonavalent | 80.9 [76.4-85.1] | 93.2 [90.3-95.6] | |
Absolute additional Impact (% of additional prevented cases) | 10.4% (p = 0.001) | 8.5% (p < 0.001) | |
Relative additional Impact | 14.7% | 10.0% | |
Oropharyngeal carcinomas (EDITH VI) | Quadrivalent | 41.4 [33.1-50.0] | 42.4 [33.8-51.1] |
Nonavalent | 41.4 [33.1-50.0] | 43.9 [35.5-52.2] | |
Absolute additional Impact (% of additional prevented cases) | 0.0% (NC) | 1.6% (p = 0.687) | |
Relative additional Impact | 0.0% | 3.8% |